Clinical Study
Postirradiation Sarcoma: Clinicopathologic Features and Role of Chemotherapy in the Treatment Strategy
Table 1
Characteristics of patients in neoadjuvant group.
| | Clinicopathologic factor | Patients |
| | Age (median, years) | 56 years |
| | Sex | | | Male | 7 | | Female | 18 |
| | Primary tumour | | | Breast cancer | 15 | | Hodgkin disease | 2 | | Bone metastase | 1 | | Sarcoma | | | – Ewing sarcoma | 2 | | – Osteosarcoma | 1 | | Retinoblastomas | 2 | | Uterus carcinoma | 1 | | Hypophysis adenoma | 1 |
| | Radiotherapy, dose delivered (mean, grays) | 53 |
| | Time to development (range) | 12 years (4–36) |
| | Size, mean cm, (range) | 6 (2–11) | | For adjuvant group | 4 (2–4) | | Neoadjuvant group | 6 (2–11) |
| | Presentation for all patients: | | | Local disease | 21 | | Metastatic disease: lung | 2 | | Brain | 1 |
| | Pathologic characteristics for neoadjuvant group | | | (response rate) | | | Leiomyosarcoma | 4 (3/4) | | Osteosarcoma | 4 (1/4) | | Angiosarcoma | 3 (1/3) | | Schwannosarcoma | 2 (1/2) | | Chondrosarcoma | 1 (0/1) | | MFH and sarcoma undifferentiated | 5 (3/5) |
| | Neoadjuvant chemotherapy | | | (response rate) | | | – CYVADIC | (2/6) | | – MAID | (6/8) | | – Doxo-CDDP | 5 (1/5) |
| | Adjuvant chemotherapy | | | – CYVADIC | 1 | | – MAID | 1 | | – Doxo-CDDP/ifosfamide | 4 |
|
|
MFH: malignant fibrous histiocytomas.
|
